Clinical trial
CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
NCT02658929 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
- Lead sponsor
- Celgene
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 22, 2015
- Completion date
- September 22, 2022
- Enrollment
- 67 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.